Journal of General Internal Medicine

, Volume 34, Issue 6, pp 804–805 | Cite as

Pharmacotherapy Prescribing to Patients with Concurrent Tobacco and Alcohol Use Disorder in a Large, Urban, Integrated Health System

  • Mat KladneyEmail author
  • Paul Joudrey
  • Chinazo O. Cunningham
  • Marcus A. Bachhuber
Concise Research Reports


Tobacco use disorder (TUD) and alcohol use disorder (AUD) are two leading causes of preventable death in the USA. These disorders frequently occur concurrently, leading to multiplicative effects on morbidity and mortality.1 Treatment of AUD and TUD with pharmacotherapy is an evidence-based way to reduce these harms. The prevalence of pharmacotherapy prescribing for patients with coexisting AUD and TUD is poorly understood. We conducted a retrospective cohort study to determine the prevalence of prescribing of AUD and TUD pharmacotherapy in a population with both diagnoses.


We conducted a retrospective cohort study using electronic health record data from Montefiore Health System between January 2010 and December 2014. Montefiore Health System is a large urban academic medical center and integrated health care system in the Bronx, New York, with over 3 million outpatient visits annually at a network of almost 100 primary and specialty care clinics.



Funding Information

This study was funded in part by grant from the National Institute on Drug Abuse of the National Institutes of Health (K24DA036955 and K08DA043050). The funding agency had no role in design of the study, collection, analysis, and interpretation of data, or in writing the manuscript.

Compliance with Ethical Standards

The study was approved by the Albert Einstein College of Medicine Institutional Review Board.

Conflict of Interest

The authors declare that they do not have a conflict of interest.


  1. 1.
    MacLean RR, Sofuoglu M, Rosenheck R. Tobacco and alcohol use disorders: evaluating multimorbidity. Addict Behav. 2018;78:59–66.CrossRefPubMedGoogle Scholar
  2. 2.
    Harris AH, Oliva E, Bowe T, Humphreys KN, Kivlahan DR, Trafton JA. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv. 2012;63(7):679–85.CrossRefPubMedGoogle Scholar
  3. 3.
    Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34(2):102–11.CrossRefPubMedGoogle Scholar
  4. 4.
    Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. J Psychiatr Res. 2015;69:150–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Mennis J, Stahler GJ. Racial and Ethnic Disparities in Outpatient Substance Use Disorder Treatment Episode Completion for Different Substances. J Subst Abuse Treat. 2016;63:25–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol. 2004;65(6):681–91.CrossRefPubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 2018

Authors and Affiliations

  • Mat Kladney
    • 1
    • 2
    Email author
  • Paul Joudrey
    • 3
    • 4
  • Chinazo O. Cunningham
    • 1
  • Marcus A. Bachhuber
    • 1
  1. 1.Division of General Internal MedicineMontefiore Medical Center/Albert Einstein College of MedicineBronxUSA
  2. 2.Division of General Internal Medicine and Clinical InnovationNew York University - Bellevue HospitalNew YorkUSA
  3. 3.VA Connecticut Healthcare SystemWest Haven CampusWest HavenUSA
  4. 4.National Clinician Scholars ProgramYale School of MedicineNew HavenUSA

Personalised recommendations